Alireza Shams
General Practice · Los Banos, CANPI 1215323183
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 92 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 18 manufacturers, the largest accounting for just 16.9% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2021 at $1,179 and has fallen 74.4% since, to $301 in 2023.
Across 92 payments — averaging $17.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$265
- Lilly USA, LLC$257
- Novo Nordisk$244
- Amarin Pharma, Inc.$134
- Boehringer Ingelheim$111
- AstraZeneca$82
- plus $478 from 12 others
What the payments were for
- Food & beverage$1,571100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 18 | $265 |
| Lilly USA, LLC | 17 | $257 |
| Novo Nordisk | 13 | $244 |
| Amarin Pharma, Inc. | 8 | $134 |
| Boehringer Ingelheim | 5 | $111 |
| AstraZeneca | 5 | $82 |
| Johnson & Johnson | 4 | $75 |
| Biohaven Pharmaceuticals, Inc. | 3 | $59 |
| Medtronic | 1 | $51 |
| Pfizer | 2 | $44 |
| Amgen | 3 | $42 |
| Adlon Therapeutics L.p. | 3 | $37 |
| Esperion Therapeutics, Inc. | 2 | $37 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $31 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $30 |
| GSK | 2 | $29 |
| Indivior Inc. | 1 | $28 |
| Eisai Inc. | 1 | $16 |
How this compares
$1,571 in reported general payments places this provider in the 85th percentile of 12,963 general practice providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Losartan Potassium | 20 | $200 |
| Amlodipine Besylate | 14 | $137 |
| Atorvastatin Calcium | 17 | $123 |
| Metformin Hcl | 12 | $35 |
Paid to pharmacies, not to this prescriber.
Other general practice in Los Banos
- Nathan LiLancaster$5.2M
- Milton McCollSan Jose$4.9M
- Frederic MollRedwood City$2.5M
- Bradley ChingUpland$1.4M
- Eric BrassTorrance$755K
- Marc GeissbergerGreenbrae$583K
- Robert CampbellLong Beach$501K
- Varo BoyerNorth Hills$482K
- Michael MiyasakiSacramento$464K
- Apolinar MadrigalCeres$419K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.